Discovery of a Potent and Selective First‐In‐Class Antagonist of GPR15 With In Vivo Anti‐Obesity Activity
Angewandte Chemie International Edition · 2026
DOI: 10.1002/anie.6947632 ↗Kurz gefasst
Fachartikel in der Zeitschrift Angewandte Chemie International Edition, 2026. Verfasst von Chong Huang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China. Hauptthemen laut MEDLINE: Receptors, G-Protein-Coupled, Anti-Obesity Agents, Obesity, Drug Discovery. Die Arbeit nennt 57 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, New Cornerstone Science Foundation.
Abstract (Originalsprache)
GPR15 (G Protein‐coupled Receptor 15), an atypical chemokine receptor, is implicated in the pathogenesis of multiple diseases, yet small‐molecule GPR15 antagonists remain undeveloped. Herein, we identify and characterize YL410 , the first‐in‐class potent and selective GPR15 antagonist. In the cAMP‐GloSensor assay, YL410 inhibits GPR15 with an IC 50 of 0.027 ± 0.005 µM, and displays high selectivity against a panel of related GPCRs and kinases. It suppresses GPR15L‐induced Jurkat T‐cell migration, and exhibits favorable pharmacokinetics and acceptable safety. Molecular docking, replicated molecular dynamics simulations, quantitative contact analyses, and mutagenesis experiments support a plausible orthosteric binding model for YL410 , maintained by a reproducible network of polar and hydrophobic contacts, which rationalizes its potent antagonism and observed structure–activity relationships (SAR). Complementary AI‐based structure predictions (AlphaFold3, Chai‐1, and Boltz) recapitulated the energetically accessible orthosteric poses but not the dynamically stable pose selected by the MD simulations, underscoring the importance of kinetic‐stability validation in antagonist pose selection. Notably, in a diet‐induced obesity (DIO) mouse model, YL410 administration induced significant weight loss and exerted blood glucose‐lowering effects. Collectively, this study presents the first potent, selective, and in vivo efficacious GPR15 antagonist, providing new insights into the development of therapeutics for the treatment of obesity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
- New Cornerstone Science Laboratory, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
- Department of Pharmacy, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
- Key Laboratory of New Drug Transformation and Evaluation of Jiangxi Province, Nanchang, China.
- Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry, West China School of Pharmacy, Sichuan University, Chengdu, China.
- Department of Ophthalmology and Laboratory of Macular Disease, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
ORCID-Profile: Chong Huang, Anjie Xia, Linli Li, Shengyong Yang
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- New Cornerstone Science Foundation
- Sichuan Science and Technology Program
- Postdoctoral Fellowship Program of CPSF
Zitieren
APA
Huang, C., Qiao, J., Zhou, M., Yang, X., Zhu, L., Ru, J., Du, L., Liu, W., Chen, Y., Xia, A., Li, L., & Yang, S. (2026). Discovery of a Potent and Selective First‐In‐Class Antagonist of GPR15 With In Vivo Anti‐Obesity Activity. Angewandte Chemie International Edition. https://doi.org/10.1002/anie.6947632
Vancouver
Huang C, Qiao J, Zhou M, Yang X, Zhu L, Ru J, et al. Discovery of a Potent and Selective First‐In‐Class Antagonist of GPR15 With In Vivo Anti‐Obesity Activity. Angewandte Chemie International Edition. 2026. doi:10.1002/anie.6947632
BibTeX
@article{Huang2026,
author = {Huang, Chong and Qiao, Jingxin and Zhou, Mengqiu and Yang, Xin and Zhu, Lengjing and Ru, Jinxiao and Du, Le and Liu, Wuxin and Chen, Yan and Xia, Anjie and Li, Linli and Yang, Shengyong},
title = {Discovery of a Potent and Selective First‐In‐Class Antagonist of GPR15 With In Vivo Anti‐Obesity Activity},
journal = {Angewandte Chemie International Edition},
year = {2026},
doi = {10.1002/anie.6947632}
}
EUVIMED